



Spectrum®
Preimplantation genetics

Designed to improve
the chance of a
healthy pregnancy

**24-Chromosome Preimplantation
Genetic Testing for Aneuploidy
(PGT-A) with Parental Support™**



What is Spectrum®
Preimplantation
Genetic Testing –
Aneuploidy (PGT-A)?




Spectrum PGT-A screens embryos to improve the chance of a healthy pregnancy. PGT-A identifies embryos with extra or missing chromosomes, also called aneuploidy.

For couples undergoing in vitro fertilization (IVF), identifying embryos with extra or missing chromosomes is important when selecting embryos for implantation. Embryos with the correct number of chromosomes (23 pairs) have the highest chance for successful implantation and lowest chance for miscarriage.



How does aneuploidy occur?

Most of the time, aneuploidy occurs by chance during the formation of an egg or sperm, or during the development of an embryo. Certain forms of aneuploidy can result in conditions that cause varying degrees of intellectual disability and birth defects. Down syndrome is a common form of intellectual disability caused by an extra copy of chromosome 21.

Normal pairing (euploid)



Abnormal pairing (aneuploid)



Who should consider Spectrum PGT-A?

Your doctor may recommend Spectrum PGT-A to reduce the risk of transferring an aneuploid embryo, or if you are considering a single embryo transfer (SET).

Providing you and your doctor greater confidence in selecting healthy embryos, Spectrum PGT-A with Parental Support™ automatically confirms parentage of embryos, can reduce time to pregnancy, and has been shown to improve the likelihood of a healthy pregnancy.


Who is at a higher risk of aneuploidy?

While any couple can have an embryo with aneuploidy, the chances can increase with the following factors:



- Maternal age over 35
- History of recurrent pregnancy loss
- Previous IVF failure
- Prior child or pregnancy with a chromosome abnormality

The chance of aneuploidy in embryos increases with the mother's age




Data from 104,788 Trophoctoderm (TE) samples screened at Natera.

How is Spectrum PGT-A different?

Spectrum's patented technology is the first of its kind to draw from advances in the Human Genome Project. Spectrum provides the most comprehensive PGT-A available and helps your doctor select an embryo most likely to result in a healthy pregnancy.

Pregnancy rates are higher when Spectrum is performed with IVF¹



On average, 1.38 embryo transfers per patient were needed to achieve a live birth in non-egg donor PGT-A cycles.¹


With Parental Support, Spectrum has the only technology to confirm parentage of an embryo

Natera's Parental Support technology uses genetic information from the parents and automatically confirms that the embryo samples match the parental samples. In fact, we are unable to obtain results if the biological parents' samples do not match the embryo samples.

How does the PGT-A process work?

PGT-A requires embryo biopsy, the removal of either a single or a small number of cells from a growing embryo. The procedure can be performed on day 3 after egg retrieval, or more commonly, on days 5–7 when embryos reach the blastocyst stage of development.

Blastocyst Terminology



What other types of samples are required for PGT-A?



A blood, cheek, or sperm sample is required from BOTH the egg and sperm contributors.

When will my results be available?



The cell(s) removed from the embryo are frozen and shipped by a medical courier to Natera for screening. Your embryo(s) remain at the clinic and are frozen, a process known as cryopreservation.



Results will be available in ~5 business days after Natera receives the egg and sperm contributor samples and the embryo biopsy sample(s).

Natera Support Services

How to learn more about Spectrum PGT-A

Natera offers complimentary pre-test Spectrum PGT-A video information sessions with visual aids to describe the PGT-A process, how Parental Support works, and the benefits and limitations of PGT-A testing. Phone information sessions with a Natera genetic counselor are also available.

To schedule a session, visit naterasession.com or call **1.877.476.4743**. A lead time of three business days prior to your biopsy date is recommended to schedule your appointment.

Post-test information sessions can be scheduled to answer questions after your doctor releases your results.

Spectrum Advantage Program:² \$99 preimplantation genetic testing for at-risk couples pursuing IVF

Natera offers Horizon carrier screening for couples who want to understand their risk of passing on a genetic condition to a child. If you and your partner screen positive as carriers with Horizon, Natera can provide Spectrum PGT-A plus Preimplantation Genetic Testing for Monogenic/Single Gene Mutations (PGT-M) at a significant cost reduction. Please contact Natera for details at **1.877.476.4743**.



Take advantage of our supporting services by texting the following keywords to 484848

PGT to learn more about the test



Watch a short informational video about Spectrum preimplantation genetic testing.

DRAW for complimentary blood draw services



Once you have your test kit, and if you choose to submit parental blood samples, find a local blood draw site or schedule an appointment with a mobile phlebotomist.

SESSION for genetic information sessions



Schedule a complimentary Spectrum Preimplantation Genetic Testing for Aneuploidies (PGT-A) pre-recorded video with visual aids session.

Learn more about Spectrum:

Call us **+1.877.476.4743**

Visit us **natera.com/spectrum**

Footnotes:

1. Simon, Alexander L. et al. Fertility and Sterility (2018), Volume 110, Issue 1, 113–121.
2. Spectrum PGT-M and PGT-A must be performed within one year of Horizon screening results. Promotional price good for one test run and not valid if patient chooses to file insurance. Shipping and batching fees apply. Restrictions apply. Both male and female must have completed a Horizon panel (Horizon 4, 14, 27, 106, 137, 274 or any other Horizon panels that include the 4 conditions on Horizon 4). Prior carrier screening or genetic testing identifying positive risk for a disorder voids special pricing.

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other FDA legal requirements for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified.

©2020 Natera, Inc. All Rights Reserved. SPC_BR_PatientBrochure_20200811_NAT-8020192

201 Industrial Road, Suite 410, San Carlos, CA 94070

Main +1 650.249.9090 | Fax 1.650.730.2272 | natera.com



Conceive. Deliver. Thrive.